CALT vs. ICPT, TVTX, ENTA, OMER, NGM, ALPN, NUVL, ALKS, PRGO, and CRNX
Should you be buying Calliditas Therapeutics AB (publ) stock or one of its competitors? The main competitors of Calliditas Therapeutics AB (publ) include Intercept Pharmaceuticals (ICPT), Travere Therapeutics (TVTX), Enanta Pharmaceuticals (ENTA), Omeros (OMER), NGM Biopharmaceuticals (NGM), Alpine Immune Sciences (ALPN), Nuvalent (NUVL), Alkermes (ALKS), Perrigo (PRGO), and Crinetics Pharmaceuticals (CRNX). These companies are all part of the "medical" sector.
Intercept Pharmaceuticals (NASDAQ:ICPT) and Calliditas Therapeutics AB (publ) (NASDAQ:CALT) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, dividends, analyst recommendations, media sentiment, profitability, risk, institutional ownership, community ranking and valuation.
Intercept Pharmaceuticals has higher revenue and earnings than Calliditas Therapeutics AB (publ). Calliditas Therapeutics AB (publ) is trading at a lower price-to-earnings ratio than Intercept Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
In the previous week, Calliditas Therapeutics AB (publ) had 31 more articles in the media than Intercept Pharmaceuticals. MarketBeat recorded 32 mentions for Calliditas Therapeutics AB (publ) and 1 mentions for Intercept Pharmaceuticals. Calliditas Therapeutics AB (publ)'s average media sentiment score of 0.30 beat Intercept Pharmaceuticals' score of 0.12 indicating that Intercept Pharmaceuticals is being referred to more favorably in the media.
Intercept Pharmaceuticals has a beta of 0.88, indicating that its stock price is 12% less volatile than the S&P 500. Comparatively, Calliditas Therapeutics AB (publ) has a beta of 1.5, indicating that its stock price is 50% more volatile than the S&P 500.
Intercept Pharmaceuticals has a net margin of -19.39% compared to Intercept Pharmaceuticals' net margin of -40.19%. Calliditas Therapeutics AB (publ)'s return on equity of -77.48% beat Intercept Pharmaceuticals' return on equity.
83.8% of Intercept Pharmaceuticals shares are owned by institutional investors. Comparatively, 2.8% of Calliditas Therapeutics AB (publ) shares are owned by institutional investors. 6.2% of Intercept Pharmaceuticals shares are owned by company insiders. Comparatively, 2.2% of Calliditas Therapeutics AB (publ) shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Intercept Pharmaceuticals received 1039 more outperform votes than Calliditas Therapeutics AB (publ) when rated by MarketBeat users. Likewise, 72.27% of users gave Intercept Pharmaceuticals an outperform vote while only 55.10% of users gave Calliditas Therapeutics AB (publ) an outperform vote.
Intercept Pharmaceuticals currently has a consensus target price of $19.00, suggesting a potential upside of 0.00%. Calliditas Therapeutics AB (publ) has a consensus target price of $35.00, suggesting a potential downside of 12.48%. Given Calliditas Therapeutics AB (publ)'s higher probable upside, research analysts clearly believe Intercept Pharmaceuticals is more favorable than Calliditas Therapeutics AB (publ).
Summary
Intercept Pharmaceuticals beats Calliditas Therapeutics AB (publ) on 13 of the 16 factors compared between the two stocks.
Get Calliditas Therapeutics AB (publ) News Delivered to You Automatically
Sign up to receive the latest news and ratings for CALT and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CALT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Calliditas Therapeutics AB (publ) Competitors List
Related Companies and Tools
